Clinical trials: Influenza Prevention
Prophylaxis: Influenza
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
The purpose of this study is to evaluate the immunologic equivalence of three consecutive lots of a cell based trivalent subunit influenza vaccine (TIVc), and to assess immunogenicity, safety and tolerability of the vaccine and…
- Trial name
- NCT02256488
- Testing
- TIVc_LOT A, TIVc_LOT B, TIVc_LOT C
- Where
- 24 sites in United States
- Volunteers
- 1,561 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to <65 years of age without pre-existing risk factors for…
- Trial name
- NCT05567783
- Testing
- VIR-2482 (450 mg), VIR-2482 (1200 mg)
- Where
- 51 sites in United States
- Volunteers
- 2,977 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Influenza, Respiratory Viral Infection
Test-and-treat for Influenza in Homeless Shelters
This study is a stepped-wedge cluster-randomized trial of on-site rapid testing and treatment for influenza in homeless shelters within the Seattle area to determine whether this strategy reduced the incidence of influenza in the…
- Trial name
- NCT04141917
- Testing
- Point-of-care molecular testing and treatment of influenza
- Where
- 9 sites in United States
- Volunteers
- 1,618 people
- Sponsor
- University of Washington
Influenza, Healthy
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season
- Trial name
- FluMist (NCT02473510)
- Testing
- Trivalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Infection
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular injection of TAK-850 in healthy pediatric Japanese participants.
- Trial name
- NCT02367885
- Testing
- TAK-850 0.5 mL injection, TAK-850 0.25 mL injection
- Where
- 2 sites in Japan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza Infection
Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in healthy Japanese adults
- Trial name
- NCT02313155
- Testing
- Subcutaneous injection of TAK-850, Intramuscular injection of TAK-850
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
The present study aims to evaluate the safety and immunogenicity of the new influenza subunit vaccine produced in Madin Darby Canine Kidney (MDCK) cells in healthy adult and elderly subjects.
- Trial name
- NCT00492063
- Testing
- Cell culture-derived trivalent subunit influenza vaccine (cTIV), Egg-derived trivalent subunit influenza vaccine (TIV)
- Where
- 5 sites in Poland
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and…
- Trial name
- Stop-Flu-2 (NCT00784784)
- Testing
- Fluviral, Zanamivir
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Influenza, Infections, Pneumococcal
System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts
The goal of this research study is to improve rates of appropriate influenza and pneumococcal vaccination among adults who receive care at a large multi-specialty group practice in central Massachusetts.
- Trial name
- NCT02266277
- Testing
- Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- University of Massachusetts, Worcester
Aspergillosis; Pulmonary, Invasive (Etiology)
Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) patients with severe influenza.
- Trial name
- POSA-FLU (NCT03378479)
- Testing
- SOC +Posaconazole 18 MG/ML (milligram/milliliter), standard of care (SOC)
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 88 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
- Trial name
- NCT05071313
- Testing
- Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine
- Where
- 19 sites in United States
- Volunteers
- 777 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Upper Respiratory Tract Infections
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu.
- Trial name
- NCT00895947
- Testing
- interferon-alpha
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Interpandemic Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Trial for annual approval of interpandemic influenza vaccines
- Trial name
- NCT00734734
- Testing
- Seasonal Influenza Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pandemic Influenza Prevention
A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.
- Trial name
- NCT03370289
- Testing
- BLB-750 Vaccine (Qinghai RG strain)
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza, Healthy
D2560C00015 FluMist Annual Safety Study 2018
This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.
- Trial name
- NCT03564444
- Testing
- Bivalent influenza vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of the candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
- Trial name
- NCT00363077
- Testing
- GSK1247446A Group, Fluarix™
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Prevention
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
The primary purpose of this study is to evaluate safety/ reactogenicity of INFLUENZA G1 mini-hemagglutinin stem-derived protein vaccine antigen (mHA), with or without Al(OH)3 adjuvant, in healthy adults greater than or equal to…
- Trial name
- NCT05901636
- Testing
- INFLUENZA G1 mHA, Al(OH)3
- Where
- 4 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.